Silverback Therapeutics Inc
SBTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$550.43M
Close$
Share Statistics
| Market cap | $550.43 Million |
|---|---|
| Enterprise Value | $542.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.74 |
| Beta | 0 |
| Outstanding Shares | 99,312,526 |
Return
| Return on Equity | -1721.80% |
|---|---|
| Return on Assets | -86.35% |
| Return on Invested Capital | -114.91% |
Valuation & Multiples
| P/E Ratio | -2.7 |
|---|---|
| PEG | -6.95 |
| Price to Sales | 5.87 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.64 |
| Enterprise Value to EBIT | -2.5 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Silverback Therapeutics Inc
54 employeesSilverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administe...